Françoise Morin

Françoise Morin

Auto-generated profile, based on publicly available information

Françoise Morin

Neuroscience Unit, University Hospital Center of Quebec–Laval University

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 February 2022 in Neurobiology of Aging
Verified
Journal Article
Open access
IGIsabelle Guisle
Isabelle Guisle
GCGeoffrey Canet
Geoffrey Canet
SPSéréna Pétry
Séréna Pétry
PFParissa Fereydouni-Forouzandeh
Parissa Fereydouni-Forouzandeh
FMFrançoise Morin
Françoise Morin
EPEmmanuel Planel
Emmanuel Planel
In Alzheimer's disease (AD), hyper-phosphorylation and aggregation of tau correlate with clinical progression and represent a valid therapeutic target. A recent 20-year prospective study revealed an association between moderate to high frequency of Finnish sauna bathing and a lower incidence of dementia and AD, but the molecular mechanisms underlying these benefits remain uncertain. Here, we tested the hypothesis that sauna-like conditions could lower tau phosphorylation by increasing body temperature. We observed a decrease in tau phosphorylation in wild-type and hTau mice as well as in neuron-like cells when exposed to higher temperatures. These effects were correlated with specific changes in phosphatase and kinase activities, but not with inflammatory or heat shock responses. We also used a drug strategy to promote thermogenesis: topical application of menthol, which led to a sustained increase in body temperature in hTau mice, concomitant with a significant decrease in tau phosphorylation. Our results suggest that sauna-like conditions or menthol treatment could lower tau pathology through mild hyperthermia, and may provide promising therapeutic strategies for AD and other tauopathies.

31 January 2025 in British Journal of Pharmacology
Verified
Journal Article
Closed access
GCGeoffrey Canet
Geoffrey Canet
CZCharleine Zussy
Charleine Zussy
MVMathieu Vitalis
Mathieu Vitalis
FMFrançoise Morin
Françoise Morin
NCNathalie Chevallier
Nathalie Chevallier
LGLaurent Givalois
Laurent Givalois

1 May 2021 in The Journal of Immunology
Verified
Journal Article
Open access
PDF file
FMFrançoise Morin
Françoise Morin
NSNoopur Singh
Noopur Singh
JMJulius Baya Mdzomba
Julius Baya Mdzomba
ADAline Dumas
Aline Dumas
APAlexandre Patenaude
Alexandre Patenaude
LVLuc Vallières
Luc Vallières
Histamine is best known for its role in allergies, but it could also be involved in autoimmune diseases such as multiple sclerosis. However, studies using experimental autoimmune encephalomyelitis (EAE), the most widely used animal model for multiple sclerosis, have reported conflicting observations and suggest the implication of a nonclassical source of histamine. In this study, we demonstrate that neutrophils are the main producers of histamine in the spinal cord of EAE mice. To assess the role of histamine by taking into account its different cellular sources, we used CRISPR–Cas9 to generate conditional knockout mice for the histamine-synthesizing enzyme histidine decarboxylase. We found that ubiquitous and cell-specific deletions do not affect the course of EAE. However, neutrophil-specific deletion attenuates hypothermia caused by IgE-mediated anaphylaxis, whereas neuron-specific deletion reduces circadian activity. In summary, this study refutes the role of histamine in EAE, unveils a role for neutrophil-derived histamine in IgE-mediated anaphylaxis, and establishes a new mouse model to re-explore the inflammatory and neurologic roles of histamine.

1 January 2010 in EMC - Anesthésie-Réanimation
Verified
Journal Article
Closed access
FSF. Souied
F. Souied
FMF. Morin
F. Morin

17 December 2025 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
RTReza Taghipour-Mirakmahaleh
Reza Taghipour-Mirakmahaleh
FMFrançoise Morin
Françoise Morin
YZYu Zhang
Yu Zhang
LBLouis Bourhoven
Louis Bourhoven
LBLouis-Charles Béland
Louis-Charles Béland
LVLuc Vallières
Luc Vallières
Autoantibodies contribute to many autoimmune diseases, yet there is no approved therapy to neutralize them selectively. A popular mouse model, experimental autoimmune encephalomyelitis (EAE), could serve to develop such a therapy, provided we can better understand the nature and importance of the autoantibodies involved. Here, we report the finding of autoantibody-secreting extrafollicular plasmablasts in EAE induced with specific myelin oligodendrocyte glycoprotein (MOG) antigens. Single-cell RNA sequencing reveals that these cells produce nonaffinity-matured IgG antibodies. These include pathogenic antibodies competing for shared binding space on MOG’s extracellular domain. Interestingly, the synthetic anti-MOG antibody 8-18C5 can prevent the binding of pathogenic antibodies from either EAE mice or people with MOG antibody disease. Moreover, an 8-18C5 variant carrying the NNAS mutation, which inactivates its effector functions, can reduce EAE severity and promote functional recovery. In brief, this study provides not only a comprehensive characterization of the humoral response in EAE models but also a proof of concept for a therapy to antagonize pathogenic anti-MOG antibodies.